Tag Archives: Brazil

Scientific American on BRIC’s IP Environment

Scientific American World View issued a special report at this year’s 2011 BIO International Convention that had several references to IP protections around the world but focused particularly on the BRIC countries (Brazil, Russia, India, and China).  See below for interesting takes on the IP environment in each country. China: Patently Ambiguous asserts that while “China’s intellectual property environment remains challenging at best” several involved on the ground in China believe that “there should be Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Keys to success for building biotech in emerging markets

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India. This year’s report will profile: Guilherme Emrich, FIR Capital (Brazil) Ge Li, WuXi Apptec (China) Kiran Mazumdar-Shaw, Biocon (India) Their opinions and advice on a diverse range of subjects is explored in a Q&A while their individual stories are told in accompanying profiles.  Don’t miss this special section in the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

BIO’s Intellectual Property Counsels Committee Seattle Meeting Topics

Join us for BIO’s Intellectual Property Counsels Committee Meeting in Seattle April 13-15.  You can find the session topics below. Whose Rights Are They, Anyway? Implications from and a Discussion on Stanford v. Roche The pending Supreme Court review of Stanford v. Roche has brought out multiple perspectives on the disposition of ownership rights in federally funded inventions under Bayh-Dole. This session will explore the different interpretations of the Act’s provisions, and their practical implications Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , , ,

BIO Comments to USTR on 2011 Special 301 Review

BIO Comments to USTR on 2011 Special 301 Review (February 15, 2011) In comments to the U.S. Trade Representative (USTR), BIO stresses the critical importance of protecting intellectual property abroad and made recommendations about which countries to include on the Priority Watch and Watch List, which to elevate as a Priority Foreigh Country, and which countries to monitor. Read the Comments (link to http://bio.org/pdfs/BIO_2011_Special_301_Submission.pdf) Read the Press Release (link to http://bio.org/news/pressreleases/newsitem.asp?id=2011_0221_01)

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

Brazilian Attorney General of the Union restricts ANVISA’s role in pharmaceutical patent review

We are receiving reports from Brazil that the Brazilian Attorney General of the Union (AGU) has adopted a position restricting the role of the National Agency for Sanitary Surveillance (ANVISA) in the patenting process for pharmaceutical products and processes.  Due to a lack of clarity in the Industrial Property Law, ANVISA has used its prior consent role to reject patent applications on the basis of novelty and inventiveness which is officially the role of the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,